|
MX382339B
(es)
*
|
2016-05-18 |
2025-03-13 |
Mirati Therapeutics Inc |
Inhibidores g12c de kras.
|
|
EP3710439B1
(en)
*
|
2017-11-15 |
2023-02-15 |
Mirati Therapeutics, Inc. |
Kras g12c inhibitors
|
|
MX2020010836A
(es)
*
|
2018-05-04 |
2021-01-08 |
Amgen Inc |
Inhibidores de kras g12c y métodos para su uso.
|
|
US11932633B2
(en)
|
2018-05-07 |
2024-03-19 |
Mirati Therapeutics, Inc. |
KRas G12C inhibitors
|
|
TW202012415A
(zh)
|
2018-05-08 |
2020-04-01 |
瑞典商阿斯特捷利康公司 |
化學化合物
|
|
ES2961253T3
(es)
*
|
2018-08-31 |
2024-03-11 |
Mirati Therapeutics Inc |
Inhibidores de KRas G12C
|
|
LT3849537T
(lt)
|
2018-09-10 |
2025-02-10 |
Mirati Therapeutics, Inc. |
Kompleksinės terapijos
|
|
US20220040181A1
(en)
|
2018-09-10 |
2022-02-10 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
WO2020055760A1
(en)
|
2018-09-10 |
2020-03-19 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
CN112955137B
(zh)
*
|
2018-09-10 |
2025-05-13 |
米拉蒂治疗股份有限公司 |
组合疗法
|
|
EP3849535A4
(en)
|
2018-09-10 |
2022-06-29 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
EP3871673B1
(en)
|
2018-10-26 |
2024-01-03 |
Taiho Pharmaceutical Co., Ltd. |
Novel indazole compound or salt thereof
|
|
MA51530B1
(fr)
|
2018-11-09 |
2024-12-31 |
F. Hoffmann-La Roche Ag |
Composés cycliques fondus
|
|
SG11202102357RA
(en)
*
|
2018-12-05 |
2021-04-29 |
Mirati Therapeutics Inc |
Combination therapies
|
|
JP7592601B2
(ja)
|
2019-01-10 |
2024-12-02 |
ミラティ セラピューティクス， インコーポレイテッド |
Ｋｒａｓ ｇ１２ｃ阻害剤
|
|
EP4249000A3
(en)
|
2019-02-12 |
2023-12-27 |
Novartis AG |
Pharmaceutical combination comprising tno155 and a krasg12c inhibitor
|
|
SG11202109451TA
(en)
|
2019-03-05 |
2021-09-29 |
Astrazeneca Ab |
Fused tricyclic compounds useful as anticancer agents
|
|
CN113874374B
(zh)
*
|
2019-05-24 |
2024-12-27 |
江苏恒瑞医药股份有限公司 |
氢化吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用
|
|
KR20220027879A
(ko)
*
|
2019-05-29 |
2022-03-08 |
상하이 한서 바이오메디컬 컴퍼니 리미티드 |
질소 함유 헤테로사이클릭 유도체의 조절제, 이의 제조방법 및 용도
|
|
CN112047939B
(zh)
*
|
2019-06-06 |
2023-05-02 |
江苏先声药业有限公司 |
一种具有抗肿瘤活性的四氢吡啶并嘧啶类化合物
|
|
CN112300153B
(zh)
*
|
2019-07-26 |
2023-06-13 |
博瑞生物医药（苏州）股份有限公司 |
一种杂环化合物、药物组合物和用途
|
|
EP4011886A4
(en)
*
|
2019-08-02 |
2023-07-26 |
Shanghai Jemincare Pharmaceuticals Co., Ltd. |
TETRACYCLIC COMPOUND, METHOD FOR PREPARATION AND USE
|
|
WO2021023247A1
(en)
*
|
2019-08-07 |
2021-02-11 |
Jacobio Pharmaceuticals Co., Ltd. |
Kras mutant protein inhibitor
|
|
CN112390788A
(zh)
*
|
2019-08-13 |
2021-02-23 |
苏州闻天医药科技有限公司 |
一种用于抑制krasg12c突变蛋白的化合物及其制备方法和用途
|
|
CN112390797A
(zh)
*
|
2019-08-15 |
2021-02-23 |
微境生物医药科技(上海)有限公司 |
新型螺环类K-Ras G12C抑制剂
|
|
CN114616232A
(zh)
*
|
2019-09-06 |
2022-06-10 |
正大天晴药业集团南京顺欣制药有限公司 |
氮杂环庚烷并嘧啶类衍生物及其医药用途
|
|
WO2021055728A1
(en)
|
2019-09-18 |
2021-03-25 |
Merck Sharp & Dohme Corp. |
Small molecule inhibitors of kras g12c mutant
|
|
US12122787B2
(en)
|
2019-09-20 |
2024-10-22 |
Shanghai Jemincare Pharmaceuticals Co., Ltd |
Fused pyridone compound, and preparation method therefor and use thereof
|
|
CA3152025A1
(en)
*
|
2019-09-24 |
2021-04-01 |
David BRIERE |
Combination therapies
|
|
CN112552295A
(zh)
*
|
2019-09-25 |
2021-03-26 |
北京加科思新药研发有限公司 |
Kras突变蛋白抑制剂
|
|
EP4041399A1
(en)
|
2019-10-02 |
2022-08-17 |
Tolremo Therapeutics AG |
Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer
|
|
CN114555586B
(zh)
*
|
2019-10-10 |
2023-06-23 |
信达生物制药(苏州)有限公司 |
Krasg12c蛋白抑制剂及其制备方法和用途
|
|
CN112694475B
(zh)
*
|
2019-10-23 |
2025-09-23 |
苏州泽璟生物制药股份有限公司 |
环烷基类和杂环烷基类抑制剂及其制备方法和应用
|
|
CA3158793A1
(en)
|
2019-10-28 |
2021-05-06 |
Merck Sharp & Dohme Corp. |
Small molecule inhibitors of kras g12c mutant
|
|
LT4053118T
(lt)
|
2019-10-30 |
2024-12-10 |
Genfleet Therapeutics (Shanghai) Inc. |
Pakeistas heterociklinis junginys su sujungtais žiedais, jo paruošimo būdas ir naudojimas farmacijoje
|
|
CA3159561A1
(en)
|
2019-11-04 |
2021-05-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
KR20220109406A
(ko)
|
2019-11-04 |
2022-08-04 |
레볼루션 메디슨즈, 인크. |
Ras 억제제
|
|
EP4055028A1
(en)
|
2019-11-04 |
2022-09-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
CN113286794B
(zh)
*
|
2019-11-04 |
2024-03-12 |
北京加科思新药研发有限公司 |
Kras突变蛋白抑制剂
|
|
CN112778301A
(zh)
*
|
2019-11-07 |
2021-05-11 |
苏州泽璟生物制药股份有限公司 |
四氢吡啶并嘧啶类抑制剂及其制备方法和应用
|
|
CN112824410A
(zh)
*
|
2019-11-21 |
2021-05-21 |
苏州泽璟生物制药股份有限公司 |
氮杂七元环类抑制剂及其制备方法和应用
|
|
WO2021108683A1
(en)
|
2019-11-27 |
2021-06-03 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
|
IL293206A
(en)
|
2019-11-27 |
2022-07-01 |
Turning Point Therapeutics Inc |
Combination therapy involving diaryl macrocyclic compounds
|
|
US12479834B2
(en)
|
2019-11-29 |
2025-11-25 |
Taiho Pharmaceutical Co., Ltd. |
Phenol compound or salt thereof
|
|
WO2021106231A1
(en)
*
|
2019-11-29 |
2021-06-03 |
Taiho Pharmaceutical Co., Ltd. |
A compound having inhibitory activity against kras g12d mutation
|
|
JP7480298B2
(ja)
*
|
2019-12-02 |
2024-05-09 |
シャンハイ インリー ファーマシューティカル カンパニー リミテッド |
酸素含有複素環化合物、その製造方法及び使用
|
|
PL3886991T3
(pl)
|
2019-12-11 |
2022-11-21 |
Eli Lilly And Company |
Inhibitory KRAS G12C
|
|
JP7644517B2
(ja)
*
|
2019-12-19 |
2025-03-12 |
ジャコバイオ ファーマスーティカルズ カンパニー リミテッド |
Ｋｒａｓ突然変異型タンパク質阻害剤
|
|
CN113004269B
(zh)
*
|
2019-12-19 |
2024-11-05 |
首药控股(北京)股份有限公司 |
Kras-G12C抑制剂杂环化合物
|
|
WO2021120890A1
(en)
|
2019-12-20 |
2021-06-24 |
Novartis Ag |
Pyrazolyl derivatives useful as anti-cancer agents
|
|
CN115135315B
(zh)
|
2019-12-20 |
2024-11-26 |
米拉蒂治疗股份有限公司 |
Sos1抑制剂
|
|
CN113045565A
(zh)
*
|
2019-12-27 |
2021-06-29 |
微境生物医药科技(上海)有限公司 |
新型K-Ras G12C抑制剂
|
|
CN112094269B
(zh)
*
|
2020-01-01 |
2021-12-07 |
上海凌达生物医药有限公司 |
一类饱和六元环并杂环类化合物、制备方法和用途
|
|
CN113087700B
(zh)
*
|
2020-01-08 |
2023-03-14 |
苏州亚盛药业有限公司 |
螺环四氢喹唑啉
|
|
GB202001344D0
(en)
|
2020-01-31 |
2020-03-18 |
Redx Pharma Plc |
Ras Inhibitors
|
|
AU2021224733A1
(en)
*
|
2020-02-20 |
2022-09-01 |
Beta Pharma, Inc. |
Pyridopyrimidine derivatives as KRAS inhibitors
|
|
WO2023205701A1
(en)
|
2022-04-20 |
2023-10-26 |
Kumquat Biosciences Inc. |
Macrocyclic heterocycles and uses thereof
|
|
TW202140450A
(zh)
*
|
2020-02-24 |
2021-11-01 |
大陸商泰勵生物科技（上海）有限公司 |
用於癌症治療的ｋｒａｓ抑制劑
|
|
MX2022011283A
(es)
*
|
2020-03-12 |
2022-11-16 |
D3 Bio Wuxi Co Ltd |
Compuestos pirimidoheterocíclicos y aplicación de los mismos.
|
|
CN115427414A
(zh)
*
|
2020-04-28 |
2022-12-02 |
贝达药业股份有限公司 |
稠环化合物及其在医药上的应用
|
|
WO2021219072A1
(zh)
*
|
2020-04-30 |
2021-11-04 |
上海科州药物研发有限公司 |
作为kras抑制剂的杂环化合物的制备及其应用方法
|
|
US11739102B2
(en)
|
2020-05-13 |
2023-08-29 |
Incyte Corporation |
Fused pyrimidine compounds as KRAS inhibitors
|
|
CN113666923A
(zh)
*
|
2020-05-15 |
2021-11-19 |
苏州泽璟生物制药股份有限公司 |
烷氧基烷基取代杂环基类抑制剂及其制备方法和应用
|
|
AU2021285032A1
(en)
|
2020-06-02 |
2022-12-08 |
Boehringer Ingelheim International Gmbh |
Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
|
|
IL298670A
(en)
*
|
2020-06-04 |
2023-01-01 |
Antengene Discovery Ltd |
Inhibitors of kras g12c protein and uses thereof
|
|
AU2021293228A1
(en)
*
|
2020-06-18 |
2023-02-09 |
Revolution Medicines, Inc. |
Methods for delaying, preventing, and treating acquired resistance to RAS inhibitors
|
|
JP2023531049A
(ja)
|
2020-06-24 |
2023-07-20 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ｓｏｓ１阻害剤及びｋｒａｓ ｇ１２ｃ阻害剤を含む抗がん剤併用療法
|
|
IL299344A
(en)
|
2020-06-25 |
2023-02-01 |
Tolremo Therapeutics Ag |
Combination of a cbp/p300 bromodomain inhibitor and a kras inhibitor for the treatment of cancer
|
|
CN113912608B
(zh)
*
|
2020-07-10 |
2023-07-14 |
江苏恒瑞医药股份有限公司 |
嘧啶并嘧啶酮类衍生物、其制备方法及其在医药上的应用
|
|
CN113980014B
(zh)
*
|
2020-07-27 |
2023-05-12 |
江苏恒瑞医药股份有限公司 |
氢化吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用
|
|
CN115956080B
(zh)
*
|
2020-08-17 |
2025-07-11 |
贝达药业股份有限公司 |
双环化合物，包含其的组合物及其应用
|
|
CA3191279A1
(en)
|
2020-08-28 |
2022-03-03 |
Yi Liu |
Heterocyclic compounds and uses thereof
|
|
US20250195521A1
(en)
|
2020-09-03 |
2025-06-19 |
Revolution Medicines, Inc. |
Use of sos1 inhibitors to treat malignancies with shp2 mutations
|
|
CA3190944A1
(en)
|
2020-09-11 |
2022-03-17 |
Mirati Therapeutics, Inc. |
Crystalline forms of a kras g12c inhibitor
|
|
CN116601151A
(zh)
*
|
2020-09-11 |
2023-08-15 |
米拉蒂治疗股份有限公司 |
Kras g12c抑制剂的晶型
|
|
WO2022052895A1
(zh)
|
2020-09-11 |
2022-03-17 |
南京明德新药研发有限公司 |
氮杂环丁烷取代化合物的晶型
|
|
IL301298A
(en)
|
2020-09-15 |
2023-05-01 |
Revolution Medicines Inc |
Indole derivatives as RAS inhibitors in cancer therapy
|
|
WO2022066805A1
(en)
|
2020-09-23 |
2022-03-31 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
|
US20220112204A1
(en)
*
|
2020-10-14 |
2022-04-14 |
Accutar Biotechnology Inc. |
Substituted dihydropyranopyrimidine compounds as kras inhibitors
|
|
WO2022087270A1
(en)
|
2020-10-23 |
2022-04-28 |
Mirati Therapeutics, Inc. |
Methods for treatment of lung cancers
|
|
CA3199295A1
(en)
*
|
2020-10-30 |
2022-05-05 |
Novartis Ag |
New crystalline forms of a kras g12c inhibitor compound
|
|
CN120887884A
(zh)
|
2020-11-06 |
2025-11-04 |
泰励生物科技（上海）有限公司 |
用于癌症治疗的KRas抑制剂
|
|
WO2022109485A1
(en)
*
|
2020-11-23 |
2022-05-27 |
Merck Sharp & Dohme Corp. |
6,7-dihydro-pyrano[2,3-d]pyrimidine inhibitors of kras g12c mutant
|
|
CN114591319B
(zh)
*
|
2020-12-04 |
2024-06-28 |
江苏先声药业有限公司 |
四氢吡啶并嘧啶类衍生物及其用途
|
|
CN116829151A
(zh)
*
|
2020-12-15 |
2023-09-29 |
米拉蒂治疗股份有限公司 |
氮杂喹唑啉泛KRas抑制剂
|
|
EP4262807A4
(en)
*
|
2020-12-15 |
2025-04-23 |
Mirati Therapeutics, Inc. |
Azachinazoline pan-KRAS inhibitors
|
|
US11999753B2
(en)
*
|
2020-12-16 |
2024-06-04 |
Mirati Therapeutics, Inc. |
Tetrahydropyridopyrimidine pan-KRas inhibitors
|
|
EP4263511A1
(en)
|
2020-12-18 |
2023-10-25 |
Amphista Therapeutics Ltd |
Novel bifunctional molecules for targeted protein degradation
|
|
CN116529249A
(zh)
*
|
2020-12-18 |
2023-08-01 |
正大天晴药业集团股份有限公司 |
吡啶并嘧啶酮类化合物
|
|
WO2022133345A1
(en)
|
2020-12-18 |
2022-06-23 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
|
WO2022140246A1
(en)
|
2020-12-21 |
2022-06-30 |
Hangzhou Jijing Pharmaceutical Technology Limited |
Methods and compounds for targeted autophagy
|
|
CN116710094A
(zh)
*
|
2020-12-22 |
2023-09-05 |
诺华股份有限公司 |
包含kras g12c抑制剂的药物组合以及kras g12c抑制剂用于治疗癌症的用途
|
|
CN114716436A
(zh)
*
|
2021-01-04 |
2022-07-08 |
广州百霆医药科技有限公司 |
Kras g12c突变抑制剂及其用途
|
|
US20240092803A1
(en)
*
|
2021-01-08 |
2024-03-21 |
Beigene Switzerland Gmbh |
Bridged compounds as kras g12d inhibitor and degrader and the use thereof
|
|
WO2022165142A1
(en)
*
|
2021-01-29 |
2022-08-04 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
MX2023009037A
(es)
*
|
2021-02-01 |
2023-08-10 |
Medshine Discovery Inc |
Compuesto de pirimidopirano.
|
|
WO2022171143A1
(zh)
*
|
2021-02-09 |
2022-08-18 |
南京明德新药研发有限公司 |
5,6,7,8-四氢吡啶[3,4-d]嘧啶化合物
|
|
WO2022187527A1
(en)
*
|
2021-03-05 |
2022-09-09 |
Nikang Therapeutics, Inc |
Quinazoline nitrile derivatives as kras inhibitors
|
|
US20250276964A1
(en)
|
2021-03-15 |
2025-09-04 |
Novartis Ag |
Benzisoxazole Derivatives and Uses thereof
|
|
WO2022194192A1
(zh)
*
|
2021-03-18 |
2022-09-22 |
四川科伦博泰生物医药股份有限公司 |
一类杂芳环化合物、其制备方法及用途
|
|
WO2022204112A1
(en)
|
2021-03-22 |
2022-09-29 |
Incyte Corporation |
Imidazole and triazole kras inhibitors
|
|
CN115124524A
(zh)
*
|
2021-03-26 |
2022-09-30 |
浙江海正药业股份有限公司 |
三环类衍生物及其制备方法和用途
|
|
CN116157400B
(zh)
*
|
2021-03-30 |
2024-10-22 |
浙江海正药业股份有限公司 |
杂环类衍生物及其制备方法和用途
|
|
IL307392A
(en)
|
2021-04-08 |
2023-12-01 |
Mirati Therapeutics Inc |
Combination therapies with PRMT5 inhibitors for cancer treatment
|
|
WO2022217042A1
(en)
*
|
2021-04-09 |
2022-10-13 |
Ikena Oncology, Inc. |
Naphthyl-substituted quinoline-4(1h)-ones and related compounds and their use in treating medical conditions
|
|
CN117479942A
(zh)
|
2021-04-09 |
2024-01-30 |
勃林格殷格翰国际有限公司 |
抗癌疗法
|
|
WO2022223020A1
(zh)
*
|
2021-04-23 |
2022-10-27 |
清华大学 |
靶向活化与失活态kras g12d的抑制剂
|
|
TW202309052A
(zh)
|
2021-05-05 |
2023-03-01 |
美商銳新醫藥公司 |
Ｒａｓ抑制劑
|
|
WO2022235870A1
(en)
|
2021-05-05 |
2022-11-10 |
Revolution Medicines, Inc. |
Ras inhibitors for the treatment of cancer
|
|
AR125921A1
(es)
*
|
2021-05-19 |
2023-08-23 |
Genentech Inc |
Terapia de combinación
|
|
US20240300980A1
(en)
*
|
2021-05-22 |
2024-09-12 |
Shanghai Kechow Pharma, Inc. |
Heterocyclic compounds as kras inhibitor, and preparation therefor and use thereof in treatment
|
|
JP2024521788A
(ja)
*
|
2021-05-27 |
2024-06-04 |
ミラティ セラピューティクス， インコーポレイテッド |
併用療法
|
|
EP4347606A4
(en)
*
|
2021-05-28 |
2025-04-02 |
Merck Sharp & Dohme LLC |
SMALL MOLECULES INHIBITING THE G12C KRAS MUTANT
|
|
EP4347041A1
(en)
*
|
2021-05-28 |
2024-04-10 |
Taiho Pharmaceutical Co., Ltd. |
Small molecule inhibitors of kras mutated proteins
|
|
EP4352053A1
(en)
|
2021-06-09 |
2024-04-17 |
Eli Lilly and Company |
Substituted fused azines as kras g12d inhibitors
|
|
US20240293558A1
(en)
|
2021-06-16 |
2024-09-05 |
Erasca, Inc. |
Kras inhibitor conjugates
|
|
WO2022262797A1
(en)
*
|
2021-06-18 |
2022-12-22 |
Shanghai Antengene Corporation Limited |
Combination of an erk inhibitor and a kras inhibitor and uses thereof
|
|
TW202317100A
(zh)
|
2021-06-23 |
2023-05-01 |
瑞士商諾華公司 |
包含ｋｒａｓ ｇ１２ｃ抑制劑的藥物組合及其用於治療癌症之用途
|
|
CN117751116A
(zh)
*
|
2021-07-07 |
2024-03-22 |
微境生物医药科技(上海)有限公司 |
作为KRas G12D抑制剂的稠环化合物
|
|
WO2023283213A1
(en)
|
2021-07-07 |
2023-01-12 |
Incyte Corporation |
Tricyclic compounds as inhibitors of kras
|
|
TW202317589A
(zh)
|
2021-07-14 |
2023-05-01 |
美商尼坎醫療公司 |
作為ｋｒａｓ抑制劑的伸烷基衍生物
|
|
WO2023283933A1
(en)
*
|
2021-07-16 |
2023-01-19 |
Silexon Biotech Co., Ltd. |
Compounds useful as kras g12d inhibitors
|
|
JPWO2023008462A1
(enExample)
|
2021-07-27 |
2023-02-02 |
|
|
|
CN113527294A
(zh)
*
|
2021-08-25 |
2021-10-22 |
都创(上海)医药开发有限公司 |
Mrtx849化合物的晶型及其制备方法和用途
|
|
US12441742B2
(en)
|
2021-08-31 |
2025-10-14 |
Incyte Corporation |
Naphthyridine compounds as inhibitors of KRAS
|
|
CA3224341A1
(en)
|
2021-09-01 |
2023-03-09 |
Novartis Ag |
Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers
|
|
EP4389751A1
(en)
|
2021-09-03 |
2024-06-26 |
Kumquat Biosciences Inc. |
Heterocyclic compounds and uses thereof
|
|
KR20240073870A
(ko)
*
|
2021-09-09 |
2024-05-27 |
미라티 테라퓨틱스, 인크. |
Adagrasib의 합성을 위한 방법 및 중간체
|
|
CN118043330A
(zh)
*
|
2021-09-29 |
2024-05-14 |
海南先声再明医药股份有限公司 |
Kras g12d抑制剂化合物及其制备方法和应用
|
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
|
WO2023066371A1
(zh)
|
2021-10-22 |
2023-04-27 |
江苏恒瑞医药股份有限公司 |
含氮的四环化合物、其制备方法及其在医药上的应用
|
|
KR20240114793A
(ko)
|
2021-11-05 |
2024-07-24 |
프론티어 메디슨즈 코포레이션 |
Kras g12c 억제제
|
|
EP4436969A2
(en)
|
2021-11-24 |
2024-10-02 |
Genentech, Inc. |
Bicyclic therapeutic compounds and methods of use in the treatment of cancer
|
|
JP2024541508A
(ja)
|
2021-11-24 |
2024-11-08 |
ジェネンテック， インコーポレイテッド |
治療用インダゾール化合物およびがんの治療における使用方法
|
|
IL312905A
(en)
|
2021-12-01 |
2024-07-01 |
Boehringer Ingelheim Int |
Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
|
|
WO2023098425A1
(zh)
*
|
2021-12-02 |
2023-06-08 |
上海和誉生物医药科技有限公司 |
一种kras抑制剂及其制备和在药学上的应用
|
|
TW202340214A
(zh)
|
2021-12-17 |
2023-10-16 |
美商健臻公司 |
做為shp2抑制劑之吡唑并吡𠯤化合物
|
|
EP4452964A1
(en)
|
2021-12-22 |
2024-10-30 |
Boehringer Ingelheim International GmbH |
Heteroaromatic compounds for the treatment of cancer
|
|
EP4456899A1
(en)
|
2021-12-28 |
2024-11-06 |
AstraZeneca UK Limited |
Combination of antibody-drug conjugate and rasg12c inhibitor
|
|
CN114409653A
(zh)
*
|
2021-12-31 |
2022-04-29 |
苏州闻天医药科技有限公司 |
一种桥环并嘧啶并环类化合物及其用途
|
|
CN118556063A
(zh)
*
|
2022-01-21 |
2024-08-27 |
上海湃隆生物科技有限公司 |
杂环类化合物、药物组合物及其应用
|
|
EP4227307A1
(en)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
|
WO2023154528A1
(en)
*
|
2022-02-11 |
2023-08-17 |
Wave Life Sciences Ltd. |
Stereoselective technologies for chiral compounds
|
|
WO2023172940A1
(en)
|
2022-03-08 |
2023-09-14 |
Revolution Medicines, Inc. |
Methods for treating immune refractory lung cancer
|
|
AU2023231139A1
(en)
|
2022-03-11 |
2024-09-05 |
Kumquat Biosciences Inc. |
Heterocyclic compounds and uses thereof
|
|
AU2023241055A1
(en)
|
2022-03-25 |
2024-10-10 |
Eli Lilly And Company |
Kras inhibitors
|
|
CA3244999A1
(en)
|
2022-03-31 |
2025-06-13 |
Eisai R&D Management Co., Ltd. |
Pharmaceutical composition for treating tumors
|
|
EP4504203A1
(en)
|
2022-04-04 |
2025-02-12 |
Sanofi |
Therapeutic combination of kras g12c inhibitor and tead inhibitor
|
|
WO2023199180A1
(en)
|
2022-04-11 |
2023-10-19 |
Novartis Ag |
Therapeutic uses of a krasg12c inhibitor
|
|
JP2025513294A
(ja)
*
|
2022-04-18 |
2025-04-24 |
ミラティ セラピューティクス， インコーポレイテッド |
アダグラシブの合成のためのプロセス及び中間体
|
|
KR20250008758A
(ko)
|
2022-05-06 |
2025-01-15 |
추가이 세이야쿠 가부시키가이샤 |
Hras 및 nras에 대한 선택적인 kras 억제 효과를 갖는 고리 화합물
|
|
CN114907387B
(zh)
*
|
2022-05-26 |
2023-11-10 |
中山大学 |
嘧啶并吡咯类kras抑制剂及其制备方法与应用
|
|
CN117164580A
(zh)
*
|
2022-05-27 |
2023-12-05 |
苏州泽璟生物制药股份有限公司 |
一种kras g12c抑制剂的制备方法及其中间体
|
|
CN117164526A
(zh)
*
|
2022-05-27 |
2023-12-05 |
苏州泽璟生物制药股份有限公司 |
2-(哌嗪-2-基)乙腈类衍生物及其制备方法和应用
|
|
KR20250022133A
(ko)
|
2022-06-10 |
2025-02-14 |
레볼루션 메디슨즈, 인크. |
거대고리 ras 억제제
|
|
US20250353844A1
(en)
*
|
2022-06-10 |
2025-11-20 |
Bristol-Myers Squibb Company |
Tetrahydropyrido 3,4-d pyrimidine derivatives as kras inhibitors
|
|
CN119731180A
(zh)
|
2022-08-05 |
2025-03-28 |
金橘生物科技公司 |
杂环化合物及其用途
|
|
WO2024040131A1
(en)
|
2022-08-17 |
2024-02-22 |
Treeline Biosciences, Inc. |
Pyridopyrimidine kras inhibitors
|
|
KR20250042846A
(ko)
|
2022-08-19 |
2025-03-27 |
미라티 테라퓨틱스, 인크. |
아다그라십 고체 제약 조성물
|
|
GB202212641D0
(en)
|
2022-08-31 |
2022-10-12 |
Jazz Pharmaceuticals Ireland Ltd |
Novel compounds
|
|
IL320639A
(en)
|
2022-11-09 |
2025-07-01 |
Revolution Medicines Inc |
Compounds, complexes and methods for their preparation and use
|
|
AU2023385486A1
(en)
|
2022-11-21 |
2025-06-05 |
Treeline Biosciences, Inc. |
Spirocyclic dihydropyranopyrimidine kras inhibitors
|
|
CN116789609A
(zh)
*
|
2023-03-03 |
2023-09-22 |
南京优氟医药科技有限公司 |
一种(r)-2-(哌嗪-2-基)乙腈盐酸盐的制备方法
|
|
CN116768804A
(zh)
*
|
2023-03-15 |
2023-09-19 |
南京优氟医药科技有限公司 |
一种(s)-2-(哌嗪-2-基)乙腈盐酸盐的制备方法
|
|
AU2024245542A1
(en)
|
2023-03-30 |
2025-08-21 |
Eli Lilly And Company |
Kras inhibitors
|
|
KR20250164828A
(ko)
|
2023-03-30 |
2025-11-25 |
레볼루션 메디슨즈, 인크. |
Ras gtp 가수분해 유도를 위한 조성물 및 이의 용도
|
|
AU2024241889A1
(en)
|
2023-03-31 |
2025-09-25 |
Eli Lilly And Company |
Kras inhibitors
|
|
AU2023439518A1
(en)
|
2023-04-06 |
2025-08-28 |
Eisai R&D Management Co., Ltd. |
Pharmaceutical composition for treating tumors
|
|
WO2024211663A1
(en)
|
2023-04-07 |
2024-10-10 |
Revolution Medicines, Inc. |
Condensed macrocyclic compounds as ras inhibitors
|
|
AU2024243852A1
(en)
|
2023-04-07 |
2025-11-06 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
KR20250169290A
(ko)
|
2023-04-14 |
2025-12-02 |
레볼루션 메디슨즈, 인크. |
Ras 억제제의 결정형, 이를 함유하는 조성물 및 이의 사용 방법
|
|
KR20250172857A
(ko)
|
2023-04-14 |
2025-12-09 |
레볼루션 메디슨즈, 인크. |
Ras 억제제의 결정형
|
|
AU2024265078A1
(en)
|
2023-05-04 |
2025-12-11 |
Revolution Medicines, Inc. |
Combination therapy for a ras related disease or disorder
|
|
WO2024229444A2
(en)
*
|
2023-05-04 |
2024-11-07 |
Frontier Medicines Corporation |
Mutant kras inhibitors and uses thereof
|
|
AU2024276994A1
(en)
|
2023-05-24 |
2025-10-23 |
Kumquat Biosciences Inc. |
Heterocyclic compounds and uses thereof
|
|
TW202510886A
(zh)
|
2023-05-31 |
2025-03-16 |
德商百靈佳殷格翰國際股份有限公司 |
作為用於預測癌症治療反應性之生物標記之存活素
|
|
CN116675690A
(zh)
*
|
2023-06-02 |
2023-09-01 |
北京康立生医药技术开发有限公司 |
一种肺癌治疗药物的制备方法
|
|
CN116478141B
(zh)
*
|
2023-06-20 |
2023-10-24 |
药康众拓(江苏)医药科技有限公司 |
氘代kras抑制剂药物及用途
|
|
WO2025007000A1
(en)
|
2023-06-30 |
2025-01-02 |
Kumquat Biosciences Inc. |
Substituted condensed tricyclic amine compounds and uses thereof as ras inhibitors
|
|
WO2025019688A2
(en)
*
|
2023-07-20 |
2025-01-23 |
Mirati Therapeutics, Inc. |
Crystalline forms of salts of adagrasib
|
|
WO2025034702A1
(en)
|
2023-08-07 |
2025-02-13 |
Revolution Medicines, Inc. |
Rmc-6291 for use in the treatment of ras protein-related disease or disorder
|
|
WO2025064848A1
(en)
|
2023-09-21 |
2025-03-27 |
Treeline Biosciences, Inc. |
Spirocyclic dihydropyranopyridine kras inhibitors
|
|
WO2025072457A1
(en)
|
2023-09-27 |
2025-04-03 |
Eli Lilly And Company |
Kras inhibitors
|
|
WO2025080946A2
(en)
|
2023-10-12 |
2025-04-17 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025085748A1
(en)
|
2023-10-20 |
2025-04-24 |
Merck Sharp & Dohme Llc |
Small molecule inhibitors of kras proteins
|
|
WO2025132549A1
(en)
|
2023-12-20 |
2025-06-26 |
Boehringer Ingelheim International Gmbh |
Cancer combination therapy using zongertinib and a kras g12c inhibitor
|
|
WO2025145207A1
(en)
|
2023-12-29 |
2025-07-03 |
Bristol-Myers Squibb Company |
Combination therapy of kras inhibitor and treg-depleting agent
|
|
WO2025171055A1
(en)
|
2024-02-06 |
2025-08-14 |
Kumquat Biosciences Inc. |
Heterocyclic conjugates and uses thereof
|
|
WO2025171296A1
(en)
|
2024-02-09 |
2025-08-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025230971A1
(en)
|
2024-04-30 |
2025-11-06 |
Kumquat Biosciences Inc. |
Macrocyclic heterocycles as anticancer agents
|
|
WO2025240847A1
(en)
|
2024-05-17 |
2025-11-20 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025245127A1
(en)
|
2024-05-21 |
2025-11-27 |
Treeline Biosciences, Inc. |
Spirocyclic dihydropyranopyrimidine kras inhibitors
|
|
WO2025242126A1
(zh)
*
|
2024-05-22 |
2025-11-27 |
上海正大天晴医药科技开发有限公司 |
一种药物组合及其应用
|
|
WO2025255438A1
(en)
|
2024-06-07 |
2025-12-11 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|